Parrado A, Rodriguez-Fernandez J M, Casares S, Noguerol P, Plaza E, Parody R, Espigado I, de Blas J M, Garcia-Solis D
Servicio de Hematología y Hemoterapia, Hospital Universitario Virgen del Rocío, Sevilla, Spain.
Leukemia. 1993 Sep;7(9):1344-8.
The in vitro stimulation of lymphocytes with interleukin-2 (IL-2) generates lymphokine-activated killer (LAK) cells with tumoricidal potential. In this work we studied the cytolytic capacity of LAK cells in 51 acute leukemia patients in complete remission (CR) after chemotherapy (CT), in 24 acute leukemia patients who had undergone autologous bone marrow transplantation (ABMT), and in a control group of 44 normal donors. In the normal donor control group the effect of non-IL-2-activated peripheral blood mononuclear cells (PBMC) against blast cells was always lower than 10% lysis, which we have taken as a lower limit for positive results. In 95% of post-CT patients, the lytic effect of PBMC was negative. LAK cells produced positive results in 82% of normal donors and in 37.5% of post-CT patients. The effect of PBMC against K562, i.e. natural killer (NK) activity, in post-CT patients as well as in post-ABMT patients was reduced in comparison with the average for normal donors. LAK cells from 25% of post-CT patients had no notable activity against K562 or Raji, nor was there any positive effect against autologous blast cells. In the rest (75%), one-half generated positive activity. We did not observe any correlation between lytic activity in PBMCs or in LAK cells, nor did we observe significant differences between lytic activity in patients with acute lymphoblastic leukemia (ALL) and those with acute myeloblastic leukemia (AML), or between patients who had undergone CT and those receiving ABMTs. These results support the use of IL-2 as a treatment against minimal residual leukemia.
用白细胞介素-2（IL-2）体外刺激淋巴细胞可产生具有杀瘤潜力的淋巴因子激活的杀伤（LAK）细胞。在本研究中，我们检测了51例化疗（CT）后处于完全缓解（CR）期的急性白血病患者、24例接受自体骨髓移植（ABMT）的急性白血病患者以及44名正常供者组成的对照组中LAK细胞的细胞溶解能力。在正常供者对照组中，未用IL-2激活的外周血单个核细胞（PBMC）对原始细胞的杀伤作用始终低于10%的裂解率，我们将此作为阳性结果的下限。在95%的CT后患者中，PBMC的裂解作用为阴性。LAK细胞在82%的正常供者和37.5%的CT后患者中产生了阳性结果。与正常供者的平均值相比，CT后患者以及ABMT后患者中PBMC对K562的作用，即自然杀伤（NK）活性降低。25%的CT后患者的LAK细胞对K562或Raji没有明显活性，对自体原始细胞也没有任何阳性作用。在其余患者（75%）中，一半产生了阳性活性。我们未观察到PBMC或LAK细胞的裂解活性之间存在任何相关性，也未观察到急性淋巴细胞白血病（ALL）患者和急性髓细胞白血病（AML）患者之间、接受CT的患者和接受ABMT的患者之间的裂解活性存在显著差异。这些结果支持将IL-2用于治疗微小残留白血病。
